[Lilly's GLP-1 medications are getting CVS coverage](https://www.marketwatch.com/story/lillys-glp-1-medications-will-soon-be-covered-by-cvs-potentially-opening-access-for-millions-of-americans-b7704707?mod=mw_rss_topstories) — that's real secular demand expansion. But here's the forensic angle: when pharma margins compress from volume competition (and they will), can LILLY sustain accrual quality?

Research these companies